Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
Identifieur interne : 001106 ( Pmc/Corpus ); précédent : 001105; suivant : 001107Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
Auteurs : Jan Balzarini ; Els Keyaerts ; Leen Vijgen ; Frank Vandermeer ; Miguel Stevens ; Erik De Clercq ; Herman Egberink ; Marc Van RanstSource :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2005.
Abstract
Url:
DOI: 10.1093/jac/dki481
PubMed: 16387746
PubMed Central: 7110042
Links to Exploration step
PMC:7110042Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pyridine <italic>N</italic>-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name></author><author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name></author><author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16387746</idno><idno type="pmc">7110042</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110042</idno><idno type="RBID">PMC:7110042</idno><idno type="doi">10.1093/jac/dki481</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">001106</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001106</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Pyridine <italic>N</italic>-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</title><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></author><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name></author><author><name sortKey="Vandermeer, Frank" sort="Vandermeer, Frank" uniqKey="Vandermeer F" first="Frank" last="Vandermeer">Frank Vandermeer</name></author><author><name sortKey="Stevens, Miguel" sort="Stevens, Miguel" uniqKey="Stevens M" first="Miguel" last="Stevens">Miguel Stevens</name></author><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name></author><author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name></author></analytic><series><title level="j">Journal of Antimicrobial Chemotherapy</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p><italic>Objectives</italic>: Evaluation of a wide variety of pyridine <italic>N</italic>-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture.</p><p><italic>Methods</italic>: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine <italic>N</italic>-oxide derivatives was monitored by spectrophotometric analysis.</p><p><italic>Results and conclusions</italic>: A wide variety of pyridine <italic>N</italic>-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine <italic>N</italic>-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50–100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine <italic>N</italic>-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id><journal-id journal-id-type="iso-abbrev">J. Antimicrob. Chemother</journal-id><journal-id journal-id-type="hwp">jac</journal-id><journal-id journal-id-type="publisher-id">jac</journal-id><journal-title-group><journal-title>Journal of Antimicrobial Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0305-7453</issn><issn pub-type="epub">1460-2091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16387746</article-id><article-id pub-id-type="pmc">7110042</article-id><article-id pub-id-type="other">dki481</article-id><article-id pub-id-type="doi">10.1093/jac/dki481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Pyridine <italic>N</italic>-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Balzarini</surname><given-names>Jan</given-names></name><xref ref-type="corresp" rid="COR1"></xref></contrib><contrib contrib-type="author"><name><surname>Keyaerts</surname><given-names>Els</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vijgen</surname><given-names>Leen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vandermeer</surname><given-names>Frank</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>Miguel</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Clercq</surname><given-names>Erik</given-names></name></contrib><contrib contrib-type="author"><name><surname>Egberink</surname><given-names>Herman</given-names></name></contrib><contrib contrib-type="author"><name><surname>Van Ranst</surname><given-names>Marc</given-names></name></contrib></contrib-group><author-notes><p>1Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium; 2Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands</p><corresp id="COR1"><label>*</label>Corresponding author. Tel: +32-16-337352; Fax: +32-16-337340; E-mail: <email>jan.balzarini@rega.kuleuven.ac.be</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2006</year></pub-date><pub-date pub-type="epub" iso-8601-date="2005-12-29"><day>29</day><month>12</month><year>2005</year></pub-date><volume>57</volume><issue>3</issue><fpage>472</fpage><lpage>481</lpage><history><date date-type="accepted"><day>12</day><month>12</month><year>2005</year></date><date date-type="received"><day>7</day><month>7</month><year>2005</year></date><date date-type="rev-recd"><day>5</day><month>10</month><year>2005</year></date><date date-type="rev-recd"><day>14</day><month>10</month><year>2005</year></date></history><permissions><copyright-statement>© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2006</copyright-year><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri xlink:href="dki481.pdf"></self-uri><abstract><title>Abstract</title><p><italic>Objectives</italic>: Evaluation of a wide variety of pyridine <italic>N</italic>-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture.</p><p><italic>Methods</italic>: FIPV and SARS-CoV were exposed to confluent Crandel feline kidney (CRFK) and simian kidney (Vero) cell cultures in the presence of serial concentrations of the test compounds. The anti-cytopathic activity of the pyridine <italic>N</italic>-oxide derivatives was monitored by spectrophotometric analysis.</p><p><italic>Results and conclusions</italic>: A wide variety of pyridine <italic>N</italic>-oxide derivatives have been found to be inhibitory against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in CRFK and simian kidney (Vero) cell cultures, respectively. The oxide part on the pyridine moiety proved indispensable for anti-coronavirus activity. The potency and virus specificity of the pyridine <italic>N</italic>-oxide derivatives varied depending the nature and specific location of substituents (i.e. alkyl, halogeno, nitro, etc.) on the different parts of the molecule. The most selective compounds were active in the higher microgram per litre range, being non-toxic at 50–100 mg/L. There was a poor structure-antiviral activity relationship (SAR) for the pyridine <italic>N</italic>-oxide derivatives against Fe-CoV and SARS-CoV. One of the most active and selective compounds was shown to inhibit Fe-CoV replication at the transcriptional level.</p></abstract><kwd-group kwd-group-type="KWD"><kwd>severe acute respiratory syndrome</kwd><kwd>feline coronavirus</kwd><kwd>FIPV</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The discovery of a novel human coronavirus (H-CoV) as the cause of the newly recognized severe acute respiratory syndrome (SARS)<sup><xref rid="B1">1</xref><xref rid="B2"></xref><xref rid="B3"></xref>–<xref rid="B4">4</xref></sup> provides a new challenge to the medical community to keep control on this disease. Although human coronaviruses cause up to 30% of colds, they rarely cause a lower respiratory tract disease, and never have a devastating effect as seen with the SARS-CoV.<sup><xref rid="B5">5</xref></sup> In contrast, animal coronaviruses are known to cause devastating epizootics of respiratory or enteric diseases in livestock and poultry.<sup><xref rid="B5">5</xref></sup> In fact, coronaviruses have been isolated from avian, porcine, feline, murine, bovine and canine species.<sup><xref rid="B5">5</xref></sup> All known coronaviruses are categorized in three serologically well-defined and unrelated groups. The SARS coronavirus is clearly new to the human population and its RNA genome differs substantially from sequences of all known coronaviruses.<sup><xref rid="B6">6</xref>,<xref rid="B7">7</xref></sup> The natural host of the SARS-CoV is most likely a Civet cat, whose virus had acquired the ability to infect humans. Interestingly, SARS-CoV can be readily isolated and grown in monkey kidney Vero cell cultures.<sup><xref rid="B8">8</xref></sup></p><p>Vaccines are available for some animal coronaviruses. However, although vaccination with live, attenuated virus is effective against porcine epidemic diarrhoea virus and avian infectious bronchitis virus, recombination of the genome of vaccine strains with wild-type coronavirus is a potential risk when applied in humans.<sup><xref rid="B5">5</xref></sup> Moreover, some vaccines against feline coronaviruses have been proven to enhance disease when vaccinated animals were exposed to wild-type virus, and thus antibody enhancement of disease is a potential risk of SARS-CoV vaccines in humans.<sup><xref rid="B5">5</xref></sup> Therefore, it is prudent to develop safe and effective drugs against SARS-CoV as quickly as possible in case a novel wide-spread outbreak would occur. The development of effective drugs against SARS-CoV may also provide new strategies for the prevention or treatment of other coronavirus diseases in animals or humans. Indeed, there are no approved drugs with proven efficacy against coronaviruses. Ribavirin has been given to SARS patients but its efficacy is unclear. Several other compounds have been recently mentioned as potential drug leads against SARS-CoV.<sup><xref rid="B9">9</xref><xref rid="B10"></xref><xref rid="B11"></xref><xref rid="B12"></xref><xref rid="B13"></xref><xref rid="B14"></xref>–<xref rid="B15">15</xref></sup></p><p>In this study, we evaluated a variety of 192 compounds that all belonged to the class of the pyridine <italic>N</italic>-oxide derivatives (<xref rid="FIG1">Figure 1</xref>) against both SARS-CoV and the type II strain of feline infectious peritonitis virus (FIPV). FIPV virus causes a severe disease in cats characterized by vasculitis and disseminated pyogranulomatous lesions in various tissues and organs. The pyridine <italic>N</italic>-oxide compounds have previously been demonstrated to be inhibitory against the human immunodeficiency virus (HIV) in cell culture.<sup><xref rid="B16">16</xref><xref rid="B17"></xref><xref rid="B18"></xref>–<xref rid="B19">19</xref></sup> Several of the pyridine <italic>N</italic>-oxide derivatives have been demonstrated to act at a post-integrational event in the replication cycle of HIV, i.e. HIV gene expression.<sup><xref rid="B18">18</xref></sup> Prolonged exposure of one of the prototype compounds (JPL-32) to DBA/2 and SCID mice demonstrated lack of acute toxicity. Moreover, a preliminary efficacy experiment showed protective activity against HIV-induced destruction of CD4-positive human T-lymphocytes in SCID mice.<sup><xref rid="B19">19</xref></sup></p><fig id="FIG1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Basic structure of the pyridine <italic>N</italic>-oxide derivatives. The ‘<italic>n</italic>’ annotation indicates that the carbon that is linked to the aryl, R<sub>2</sub> and pyridinesulphone moieties can be extended to a longer alkyl chain.</p></caption><graphic xlink:href="dki481f1"></graphic></fig><p>Our aim in the present study was to reveal whether pyridine <italic>N</italic>-oxide derivatives are endowed with inhibitory activity against SARS-CoV and FIPV, and whether the antiviral potencies of the pyridine <italic>N</italic>-oxide derivatives previously reported for HIV could be correlated with their antiviral activity against SARS-CoV and FIPV.</p></sec><sec><title>Materials and methods</title><sec><title>Compounds</title><p>The structures of the compounds have been reported previously.<sup><xref rid="B16">16</xref></sup></p></sec><sec><title>Cell culture and viruses</title><p>The SARS-CoV (Frankfurt-1 strain) was kindly provided by Prof. Dr H. F. Rabenau (Johann Wolfgang Goethe University, Frankfurt, Germany). Vero E6 cells were propagated in minimal essential medium (MEM; Gibco Life Technologies, Rockville, MD, USA) supplemented with 10% fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 2 mM <sc>l</sc>-glutamine (Gibco) and 1.4% sodium bicarbonate (Gibco Life Technologies, Rockville, MD, USA). Virus-infected cells were maintained at 37°C in a 5% CO<sub>2</sub> atmosphere in MEM supplemented with 2% FCS. The Fe-CoV (FIPV strain 1146) was originally isolated by McKeirnan <italic>et al</italic>.<sup><xref rid="B20">20</xref></sup> and propagated from Crandel feline kidney (CRFK) cells maintained in RPMI-1640 medium (Gibco) and supplemented with 10% fetal bovine serum (Harlan Sera-Lab Ltd, Loughborough, UK), 2 mM <sc>l</sc>-glutamine (Gibco) and 0.075% sodium bicarbonate (Gibco). Virus-infected cells were maintained at 37°C in RPMI-1640 medium supplemented with 2% FCS.</p></sec><sec><title>Antiviral and cytostatic activity assays</title><p>Antiviral activity and cytotoxicity measurements were based on the viability of Vero cells that had been infected or mock-infected with 100 CCID<sub>50</sub> (50% cell culture infective dose) of the SARS-CoV or CRFK cells infected or mock-infected with 100 CCID<sub>50</sub> FIPV in the presence of various concentrations of the test compounds. The virus–drug mixture was not removed after the adsorption phase of the virus infection. The compounds were present throughout the whole time period of the experiment. Three days (SARS-CoV) or four days (Fe-CoV) after the infection, the number of viable cells was quantified by a tetrazolium-based colorimetric method as previously described for HIV by Pauwels <italic>et al</italic>.<sup><xref rid="B21">21</xref></sup> The medium was aspirated and replaced by a solution of MTT [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazonium]/PMS (phenazinemethosulphate) according to the manufacturer's instructions (Promega Corporation, Madison, WI, USA). The results are given as the mean (±SD) of at least 2–3 independent experiments. The cytotoxic concentration was determined as the concentration of the compound that reduced cell viability by 50% (CC<sub>50</sub> or 50% cytotoxic concentration), and the antivirally effective concentration was determined as the compound concentration that prevented the viral cytopathic effect by 50% of the control value (EC<sub>50</sub> or 50% effective concentration). Thus, both the CC<sub>50</sub> and the EC<sub>50</sub> values were calculated from the absorbance values, and the EC<sub>50</sub>s were obtained after deduction of the absorbance value of the control cultures from the absorbance value of the virus-infected cultures.</p></sec><sec><title>Time-of-addition experiments</title><p>To reveal at what stage in the infection cycle the compounds are inhibitory, a time-of-addition (TOA) experiment was carried out in which CRFK cell cultures were infected with a high dose (≥1000 CCID<sub>50</sub>) of FIPV. The pyridine <italic>N</italic>-oxide <bold>45</bold> was used at 50 mg/L. At different time points post-infection (i.e. 0, 1, 2.5, 5, 7, 14, 25, 34, 49 and 72 h), the drug was added to the infected cell cultures. After 72 h, full cytopathic activity was noticed for the control cultures. Optical reading of the MTT-exposed cell cultures was then performed to quantify the protective effect of the test compounds added at the different time points against virus-induced cytopathicity.</p></sec></sec><sec><title>Results</title><sec><title>Antiviral activity of pyridine N-oxide derivatives with modifications in the phenyl ring</title><p>A variety of substituted pyridine <italic>N</italic>-oxide derivatives have been evaluated in which a sulphone (SO<sub>2</sub>), a sulphoxide (SO) or a thio ether (S) links the unsubstituted pyridine <italic>N</italic>-oxide group through a CH<sub>2</sub> to the phenyl moiety (<xref rid="TBL1">Table 1</xref>). The anti-coronavirus activities ranged between 0.29 and >100 mg/L for FIPV and between 4.2 and >100 mg/L for SARS-CoV depending on the nature and the locations of the substituents in the phenyl moiety. As a rule, when antiviral activity was recorded, the anti-FIPV activity was always more pronounced than the anti-SARS-CoV activity. Compounds that were weakly inhibitory against FIPV did not show detectable antiviral activity against SARS-CoV. Generally, sulphide and sulphoxide derivatives showed poor, if any, antiviral activity against both coronaviruses except for <bold>27</bold> and <bold>35</bold> that were inhibitory to Fe-CoV (EC<sub>50</sub>: <10 mg/L), but not to SARS-CoV (EC<sub>50</sub>: >100 mg/L). The position of one or more alkyl or alkoxy groups on the phenyl moiety does not play a marked role in the eventual anti-coronavirus potency of the test compounds (compare compounds <bold>4–35</bold>). This was generally also observed for the halogen-, nitro- and cyano-substituted compounds. The most potent antiviral activity was noted for the trichloro (<bold>44</bold>), pentachloro (<bold>45</bold>), methyl/tetrachloro (<bold>46</bold>) and nitro (<bold>52</bold>) derivatives (EC<sub>50</sub>: 0.3–0.9 mg/L for Fe-CoV and ∼17–20 mg/L for SARS-CoV) virtually completely lacking cytotoxic activity against the CRFK and Vero cell cultures (MIC: ≥100 mg/L). Only a few compounds were found to be markedly active (EC<sub>50</sub>: <5 mg/L) against FIPV but not active against SARS-CoV at subtoxic concentrations (<bold>14</bold>, <bold>20</bold>, <bold>23</bold>, <bold>26</bold>, <bold>28</bold>, <bold>43</bold>, <bold>54</bold>, <bold>55</bold>, <bold>59</bold>, <bold>60</bold>, <bold>64</bold>). Instead, compounds that were more active against SARS-CoV than Fe-CoV were not found.
</p><table-wrap id="TBL1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Antiviral activity of pyridine <italic>N</italic>-oxide derivatives modified in the phenyl moiety</p></caption><graphic xlink:href="dki481t1"></graphic><table-wrap-foot><fn id="TBLFN1"><label>a</label><p>EC<sub>50</sub>, 50% effective concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures. Data are taken from ref. (<xref rid="B16">16</xref>).</p></fn><fn id="TBLFN2"><label>b</label><p>IC<sub>50</sub>, 50% inhibitory (cytostatic) concentration required to inhibit CEM cell proliferation by 50%. Data were obtained by counting the number of CEM cells using a Coulter Particle Counter (Coulter Electronics, Miami, FL).</p></fn><fn id="TBLFN3"><label>c</label><p>CC<sub>50</sub>, cytotoxic concentration required to cause a decreased viability of the CRFK and Vero cell cultures by 50%. Data were obtained by a spectrophotometric analysis using the MTT dye exclusion method.</p></fn><fn id="TBLFN4"><label>d</label><p>Abbreviations: Me, methyl; Et, ethyl; Prop, propyl; iProp, isopropyl; But, butyl; Pent, pentyl; Phe, phenyl; Bz, benzyl.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Antiviral activity of pyridine N-oxide derivatives modified in the bridge (Z) part of the molecule</title><p>A series of compounds were made that contain a substitution (<italic>Z</italic>) at the CH<sub>2</sub> position linking the phenyl group to the other part of the molecule (<xref rid="TBL2">Table 2</xref>). Several alkyl/halogeno-substituted compounds were markedly inhibitory against SARS-CoV (EC<sub>50</sub>: 2.1–2.7 mg/L) being not measurably active against FIPV (i.e. <bold>75</bold>–<bold>78</bold>). However, it should be noticed that these compounds proved markedly cytotoxic to both CRFK and Vero cell cultures, and therefore potential anti-FIPV activity may have been masked by the cellular toxicity or, alternatively, the observed anti-SARS-CoV activity has to be interpreted as a toxic rather than a specific antiviral effect. For all other antivirally active compounds—as already noted for the unsubstituted series of compounds discussed above—anti-FIPV activity was more pronounced than the anti-SARS-CoV activity. Compound <bold>72</bold> represents the only exception where anti-SARS-CoV activity was noticed (EC<sub>50</sub>: 13 mg/L) without a trace of anti-FIPV activity. Intriguingly, this compound was toxic for CRFK cells (CC<sub>50</sub>: 1.3 mg/L) but not for Vero cells (CC<sub>50</sub>: >100 mg/L).
</p><table-wrap id="TBL2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Antiviral activity of pyridine <italic>N</italic>-oxide derivatives modified in the Z part of the molecule</p></caption><graphic xlink:href="dki481t2"></graphic><table-wrap-foot><fn id="TBLFN5"><label>a</label><p>EC<sub>50</sub>, 50% effective concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures. Data taken from ref. (<xref rid="B16">16</xref>).</p></fn><fn id="TBLFN6"><label>b</label><p>IC<sub>50</sub>, 50% inhibitory (cytostatic) concentration required to inhibit CEM cell proliferation by 50%.</p></fn><fn id="TBLFN7"><label>c</label><p>CC<sub>50</sub>, cytotoxic concentration required to cause a decreased viability of the CRFK and Vero cell cultures by 50%.</p></fn><fn id="TBLFN8"><label>d</label><p>Introduction of a Z entity introduces chirality in the molecules. The compounds represent racemic mixtures.</p></fn><fn id="TBLFN9"><label>e</label><p>Abbreviations: Me, methyl; Et, ethyl; Prop, propyl; Isobut, isobutyl; Hept, heptyl; Undec, undecyl.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Antiviral activity of pyridine N-oxide derivatives containing a cyano-substituted ethylene bridge between the thioether and the phenyl moiety</title><p>While the <bold>116</bold>- and <bold>122</bold>-sulphide derivatives were markedly more active against FIPV than SARS-CoV, the dihalogen-substituted pyridine <italic>N</italic>-oxide derivative <bold>120</bold> was 4-fold more effective against SARS-CoV than FIPV (<xref rid="TBL3">Table 3</xref>). Also, <bold>117</bold> and <bold>118</bold> showed antiviral activity against SARS-CoV but not FIPV. Intriguingly, the active compounds in this series of pyridine <italic>N</italic>-oxide derivatives contained exclusively a sulphide moiety whereas the sulphones <bold>119</bold> and <bold>121</bold> were entirely devoid of antiviral activity. An opposite trend of (in)activity with respect to sulphones versus sulphides and sulphoxides was previously found for the first and second series of compounds depicted in <xref rid="TBL1">Tables 1</xref> and <xref rid="TBL2">2</xref>.
</p><table-wrap id="TBL3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Antiviral activity of pyridine <italic>N</italic>-oxide derivatives containing an ethylene bridge between the thioether and the phenyl moiety</p></caption><graphic xlink:href="dki481t3"></graphic><table-wrap-foot><fn id="TBLFN10"><p>Abbreviations: Me, methyl; Oct, octyl.</p></fn><fn id="TBLFN11"><label>a</label><p>EC<sub>50</sub>, 50% effective concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures. Data are taken from ref. (<xref rid="B16">16</xref>).</p></fn><fn id="TBLFN12"><label>b</label><p>IC<sub>50</sub>, 50% inhibitory (cytostatic) concentration required to inhibit CEM cell proliferation by 50%.</p></fn><fn id="TBLFN13"><label>c</label><p>CC<sub>50</sub>, cytotoxic concentration required to cause a decreased viability of the CRFK and Vero cell cultures by 50%.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Anti-coronavirus activity of pyridine N-oxide derivatives modified at the pyridine oxide and phenyl and Z part of the molecule</title><p>Among the pyridine <italic>N</italic>-oxide derivatives that contain alkyl, alkoxy, halogen or nitro substituents on the pyridine moiety in addition to substituents on the phenyl and the bridge between the pyridine thioether and the phenyl, a few compounds were endowed with a pronounced anti-FIPV selectivity (<xref rid="TBL4">Table 4</xref>). Indeed, <bold>155</bold> had an EC<sub>50</sub> of 0.49 mg/L against FIPV being inactive against SARS-CoV. This compound was not cytotoxic at 100 mg/L, and therefore represents the most selective anti-FIPV compound among all pyridine <italic>N</italic>-oxide derivatives tested. The location of the chloro substituent on the pyridine moiety seems crucial, since moving the chloro from Y<sub>1</sub> to the Y<sub>2</sub>, Y<sub>3</sub> or Y<sub>4</sub> position resulted in completely inactive compounds (<bold>158</bold>, <bold>161</bold>, <bold>165</bold>). Besides <bold>155</bold>, also <bold>132</bold>, <bold>133</bold>, <bold>142</bold> and <bold>146</bold> can be regarded as highly selective anti-Fe-CoV compounds. As observed before, none of the compounds was more inhibitory against SARS-CoV than against Fe-CoV. Compounds <bold>157</bold> and <bold>159</bold> were the most interesting compounds that had comparable (potent) activity against both SARS-CoV and FIPV (EC<sub>50</sub>: 1.7–4.2 mg/L), being poorly cytotoxic (<bold>157</bold>; CC<sub>50</sub>: 62 mg/L for CRFK and >100 mg/L for Vero cell cultures) to moderately cytotoxic (<bold>159</bold>; CC<sub>50</sub>: 13 mg/L for CRFK and 71 mg/L for Vero cell cultures) (<xref rid="TBL4">Table 4</xref>).
</p><table-wrap id="TBL4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Antiviral activity of pyridine <italic>N</italic>-oxide derivatives modified in the pyridine oxide and phenyl and Z part of the molecule</p></caption><graphic xlink:href="dki481t4"></graphic><table-wrap-foot><fn id="TBLFN14"><label>a</label><p>EC<sub>50</sub>, 50% effective concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures. Data are taken from ref. (<xref rid="B16">16</xref>).</p></fn><fn id="TBLFN15"><label>b</label><p>IC<sub>50</sub>, 50% inhibitory (cytostatic) concentration required to inhibit CEM cell proliferation by 50%.</p></fn><fn id="TBLFN16"><label>c</label><p>CC<sub>50</sub>, cytotoxic concentration required to cause a decreased viability of the CRFK and Vero cell cultures by 50%.</p></fn><fn id="TBLFN17"><label>d</label><p>Introduction of a Z entity introduces chirality in the molecules. The compounds represent racemic mixtures.</p></fn><fn id="TBLFN18"><label>e</label><p>Abbreviations: Me, methyl; Et, ethyl; t-bu, tertiary butyl.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Anti-coronavirus activity of reduced pyridine N-oxide derivatives</title><p>A total of 23 compounds that lacked the oxygen at the N-atom of the pyridine moiety were evaluated for antiviral activity (<xref rid="TBL5">Table 5</xref>). As a rule, lack of the oxide moiety proved detrimental for anti-SARS-CoV and anti-FIPV activity. Indeed, virtually none of the test compounds was antivirally active at subtoxic concentrations. Only <bold>173</bold> (FIPV), <bold>184</bold> (SARS-CoV) and <bold>185</bold> (SARS-CoV) showed antiviral activity, although their EC<sub>50</sub>s were rather close to their CC<sub>50</sub>s.
</p><table-wrap id="TBL5" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Antiviral activity of pyridine derivatives</p></caption><graphic xlink:href="dki481t5"></graphic><table-wrap-foot><fn id="TBLFN19"><label>a</label><p>EC<sub>50</sub>, 50% effective concentration required to inhibit HIV-induced giant cell formation in CEM cell cultures. Data are taken from ref. (<xref rid="B16">16</xref>).</p></fn><fn id="TBLFN20"><label>b</label><p>IC<sub>50</sub>, 50% inhibitory (cytostatic) concentration required to inhibit CEM cell proliferation by 50%.</p></fn><fn id="TBLFN21"><label>c</label><p>CC<sub>50</sub>, cytotoxic concentration required to cause a decreased viability of the CRFK and Vero cell cultures by 50%.</p></fn><fn id="TBLFN22"><label>d</label><p>Introduction of a Z entity introduces chirality in the molecules. The compounds represent racemic mixtures.</p></fn><fn id="TBLFN23"><label>e</label><p>Abbreviation: Me, methyl.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>The pyridine <italic>N</italic>-oxide derivatives represent a unique class of antivirals. Several members have previously been found to be active against HIV-1 and/or HIV-2, and human cytomegalovirus (HCMV), but not against several other DNA viruses including herpes simplex virus type 1 and type 2, varicella-zoster virus and vaccinia virus or against RNA viruses including vesicular stomatitis virus, reovirus-1, polio virus, Coxsackie virus B4, Semliki forest virus and parainfluenza virus.<sup><xref rid="B16">16</xref></sup> Surprisingly, the pyridine <italic>N</italic>-oxides were now also found inhibitory against coronaviruses, in particular against the feline coronavirus type II strain of FIPV and the SARS coronavirus strain Frankfurt-1. Such an antiviral selectivity spectrum is rather unusual. Interestingly, as previously noted between HIV-1, HIV-2 and HCMV, there is no close correlation for the antiviral activity of the pyridine <italic>N</italic>-oxides against HIV-1 on the one hand, and FIPV and SARS-CoV on the other hand (<italic>r</italic> = 0.29 and 0.47, respectively) (compare the antiviral activities of the test compounds against HIV-1 with those found against the coronaviruses given in <xref rid="TBL1">Tables 1</xref>–<xref rid="TBL5">5</xref>). Also, there is no correlation for the EC<sub>50</sub>s between FIPV and SARS-CoV in cell culture (<italic>r</italic> = 0.06). Indeed, there were a number of compounds that proved exclusively inhibitory to FIPV and not to SARS-CoV. Among these, only <bold>63</bold> and <bold>116</bold> were not active against HIV-1. The other compounds that discriminated between FIPV and SARS-CoV showed also activity against HIV-1.</p><p>The pyridine <italic>N</italic>-oxide derivatives have a peculiar mechanism of antiviral action. It has previously been shown that pyridine <italic>N</italic>-oxide derivatives such as <bold>11</bold>, <bold>17</bold>, <bold>45</bold> and <bold>160</bold> act at a step in the HIV-1 and HIV-2 replication cycle that follows proviral integration, i.e. at the HIV gene expression level.<sup><xref rid="B18">18</xref></sup> In this respect, the pyridine <italic>N</italic>-oxide derivatives inhibit binding of nuclear NF-κB to DNA in the intact cell system and regeneration of IκBα after TNF-α stimulation.<sup><xref rid="B18">18</xref>,<xref rid="B19">19</xref></sup> Thus, targeting of a cellular protein in the transactivation process is the most likely explanation for the anti-HIV/HCMV activity of the pyridine <italic>N</italic>-oxide derivatives. The molecular target for the anti-coronavirus activity is still unclear. Coronaviruses replicate in the cytoplasm, and not in the nucleus. However, a TOA experiment in which the pyridine <italic>N</italic>-oxide derivative <bold>45</bold> was added at different time points after Fe-CoV infection of CRFK cell cultures revealed that addition of the compound to the virus-infected cells could be substantially delayed before losing its antiviral potential (<xref rid="FIG2">Figure 2</xref>). A similar TOA experiment against HIV in human lymphocyte CEM cell cultures revealed also a post-integrational event as a target of <bold>45</bold> in the replication cycle of HIV.<sup>18</sup> Thus, compound <bold>45</bold> inhibits virus replication at an event that is clearly located after viral entry and acts most likely during the transcription process of the virus replication cycle. However, not only the differences in antiviral activity but also cytotoxicity depending on the virus type (HIV, Fe-CoV, SARS-CoV) or cell type (CEM, CRFK, Vero) is indicative for a rather specific interaction with a cellular and/or a viral factor to explain the rather unpredictable antiviral and cytostatic properties of the pyridine <italic>N</italic>-oxide derivatives. In this respect, while the oxide form of the compounds seems to be crucial to maintain anti-coronavirus activity, this requirement was much less stringent to keep anti-HIV-1 activity (compare anti-HIV and anti-coronavirus activity for the reduced pyridine <italic>N</italic>-oxides in <xref rid="TBL5">Table 5</xref>).
</p><fig id="FIG2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Effect of different time points of addition of compound <bold>45</bold> to Fe-CoV-infected CRFK cell cultures on protection against virus-induced cytopathicity.</p></caption><graphic xlink:href="dki481f2"></graphic></fig><p>Despite the pronounced cytostatic activity noticed in proliferating human CEM lymphocyte cell culture, pyridine <italic>N</italic>-oxide derivatives are often poorly cytotoxic in confluent CRFK and Vero cell cultures, resulting in pronounced selectivity indices for several compounds (exceeding two orders of magnitude). Moreover, compound <bold>45</bold>, which represents one of the most inhibitory and selective anti-coronavirus compounds in this study (lacking any pronounced selectivity against HIV-1 in CEM cell cultures), has been administered to mice at 15 mg/kg/day for 10 days (upon continuous release through Alzet pumps) or at 100 mg/kg/day intraperitoneally for 10 consecutive days. Under these experimental conditions, <bold>45</bold> did not result in any visible signs of toxicity or side effects in the drug-exposed animals. These observations may justify more in-depth studies on the pharmacokinetics of <bold>45</bold> and related compounds and on the potential of pyridine <italic>N</italic>-oxide derivatives as anti-coronavirus drugs <italic>in vivo</italic>.</p><p>In conclusion, the selective anti-coronavirus activity found for several pyridine <italic>N</italic>-oxide derivatives in cell culture may warrant further pre-clinical investigations to reveal the potential of this class of antiviral drugs as selective inhibitors of coronaviruses, including SARS-CoV infection in humans and Fe-CoV infection in cats.</p></sec><sec><title>Transparency declarations</title><p>The authors have no financial or any other conflict of interest regarding the contents of the investigations.</p></sec></body><back><ack><p>Mrs Lizette van Berckelaer is gratefully acknowledged for excellent technical assistance and Mrs Christiane Callebaut for dedicated editorial help. The compounds were kindly provided by Dr John Lacadie and Dr Jim Pierce at Crompton Corporation (Middlebury, CT, USA). The research was supported by the René Descartes Prize-2001 of the European Commission (no. HPAW-2002-90001) and by the European Research Project SARS-DTV (contract no. SP22-CT-2004).</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">Drosten C, Gunther S, Preiser W <italic>et al</italic> Identification of a novel coronavirus in patients with severe acute respiratory syndrome. <source>N Engl J Med</source><year>2003</year>; <volume>348</volume>: <fpage>1967</fpage>–76.<pub-id pub-id-type="pmid">12690091</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">Ksiazek TG, Erdman D, Goldsmith CS <italic>et al</italic> A novel coronavirus associated with severe acute respiratory syndrome. <source>N Engl J Med</source><year>2003</year>; <volume>348</volume>: <fpage>1953</fpage>–66.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">Kuiken T, Fouchier RA, Schutten M <italic>et al</italic> Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. <source>Lancet</source><year>2003</year>; <volume>362</volume>: <fpage>263</fpage>–70.<pub-id pub-id-type="pmid">12892955</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">Peiris JS, Lai ST, Poon LL <italic>et al</italic> Coronavirus as a possible cause of severe acute respiratory syndrome. <source>Lancet</source><year>2003</year>; <volume>361</volume>: <fpage>1319</fpage>–25.<pub-id pub-id-type="pmid">12711465</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">Holmes KV. SARS-associated coronavirus. <source>N Engl J Med</source><year>2004</year>; <volume>348</volume>: <fpage>1948</fpage>–51.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">Rota PA, Oberste MS, Monroe SS <italic>et al</italic> Characterization of a novel coronavirus associated with severe acute respiratory syndrome. <source>Science</source><year>2003</year>; <volume>300</volume>: <fpage>1394</fpage>–9.<pub-id pub-id-type="pmid">12730500</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">Marra MA, Jones SJM, Astell CR <italic>et al</italic> The genome sequence of the SARS-associated coronavirus. <source>Science</source><year>2003</year>; <volume>300</volume>: <fpage>1399</fpage>–404.<pub-id pub-id-type="pmid">12730501</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">Ng ML, Tan SH, See EE <italic>et al</italic> Proliferative growth of SARS coronavirus in Vero B6 cells. <source>J Gen Virol</source><year>2003</year>; <volume>84</volume>: <fpage>3291</fpage>–303.<pub-id pub-id-type="pmid">14645910</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">Chan KS, Lai ST, Chu CM <italic>et al</italic> Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. <source>Hong Kong Med J</source><year>2003</year>; <volume>9</volume>: <fpage>399</fpage>–406.<pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">Cinatl J, Michaelis M, Scholtz M <italic>et al</italic> Role of interferons in the treatment of severe acute respiratory syndrome. <source>Expert Opin Biol Ther</source><year>2004</year>; <volume>4</volume>: <fpage>827</fpage>–36.<pub-id pub-id-type="pmid">15174965</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">Cinatl J, Morgenstern B, Bauer G <italic>et al</italic> Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. <source>Lancet</source><year>2003</year>; <volume>361</volume>: <fpage>2045</fpage>–6.<pub-id pub-id-type="pmid">12814717</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">Wu CJ, Jan JT, Chen CM <italic>et al</italic> Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. <source>Antimicrob Agents Chemother</source><year>2004</year>; <volume>48</volume>: <fpage>2693</fpage>–6.<pub-id pub-id-type="pmid">15215127</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">Yamamoto N, Yang R, Yoshinaka Y <italic>et al</italic> HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. <source>Biochem Biophys Res Commun</source><year>2004</year>; <volume>318</volume>: <fpage>719</fpage>–25.<pub-id pub-id-type="pmid">15144898</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">Keyaerts E, Vijgen L, Chen L <italic>et al</italic> Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. <source>Int J Infect Dis</source><year>2004</year>; <volume>8</volume>: <fpage>223</fpage>–6.<pub-id pub-id-type="pmid">15234326</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">Keyaerts E, Vijgen L, Maes P <italic>et al</italic> In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. <source>Biochem Biophys Res Commun</source><year>2004</year>; <volume>323</volume>: <fpage>264</fpage>–8.<pub-id pub-id-type="pmid">15351731</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal">Balzarini J, Stevens M, Andrei G <italic>et al</italic> Pyridine oxide derivatives: structure-activity relationship for inhibition of human immunodeficiency virus and cytomegalovirus replication in cell culture. <source>Helv Chim Acta</source><year>2002</year>; <volume>85</volume>: <fpage>2961</fpage>–74.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">Stevens M, Pannecouque C, De Clercq E <italic>et al</italic> Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. <source>Antimicrob Agents Chemother</source><year>2003</year>; <volume>47</volume>: <fpage>2951</fpage>–7.<pub-id pub-id-type="pmid">12937000</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">Stevens M, Pannecouque C, De Clercq E <italic>et al</italic> Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. <source>Antimicrob Agents Chemother</source><year>2003</year>; <volume>47</volume>: <fpage>3109</fpage>–16.<pub-id pub-id-type="pmid">14506017</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">Balzarini J, Stevens M, De Clercq E <italic>et al</italic> Pyridine <italic>N</italic>-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. <source>J Antimicrob Chemother</source><year>2005</year>; <volume>55</volume>: <fpage>135</fpage>–8.<pub-id pub-id-type="pmid">15650002</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">McKeirnan AJ, Evermann JF, Hargis A <italic>et al</italic> Isolation of feline coronaviruses from two cats with diverse disease manifestations. <source>Feline Pract</source><year>1981</year>; <volume>11</volume>: <fpage>17</fpage>–20.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">Pauwels R, Balzarini J, Baba M <italic>et al</italic> Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. <source>J Virol Methods</source><year>1988</year>; <volume>20</volume>: <fpage>309</fpage>–21.<pub-id pub-id-type="pmid">2460479</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001106 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001106 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7110042
|texte= Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:16387746" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |